Home > Insider Trading > Filing (0001209191-16-128045)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
949858	Oncogenex Pharmaceuticals Inc.	OGXI	In Vitro & In Vivo Diagnostic Substances (2835)	954343413

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442675	Daniel Scott Cormack	400-1001 W. Broadway Vancouver A1 V6H 4B1	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-06-13	9,375	$0.00	134,284	No	4	M	Direct
Common Stock	Disposition	2016-06-13	4,856	$1.03	129,428	No	4	S	Direct
Common Stock	Acquisiton	2016-06-13	5,000	$0.00	73,743	No	4	M	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	M	Indirect	By Spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit (RSU)	Disposition	2016-06-13	9,375	$0.00	9,375	$0.00
Common Stock	Restricted Stock Unit	Disposition	2016-06-13	5,000	$0.00	5,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,750		2018-06-12	No	4	M	Direct
10,000		2018-06-12	No	4	M	Indirect

Footnotes

Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.01 to $1.045 per share, inclusive. The reporting person hereby undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of June 12, 2014; and (ii) the first day thereafter during which the issuer's trading window is open, subject to the reporting person's provision of service to the issuer on each vesting date.